Using Fludarabine to Reduce Exposure to Alkylating Agents in Children with Sickle Cell Disease Receiving Busulfan, Cyclophosphamide, and Antithymocyte Globulin Transplant Conditioning: Results of a Dose De-Escalation Trial  by Horan, John T. et al.
Biol Blood Marrow Transplant 21 (2015) 900e905Biology of Blood and
Marrow Transplantation
journal homepage: www.bbmt.orgUsing Fludarabine to Reduce Exposure to Alkylating Agents
in Children with Sickle Cell Disease Receiving Busulfan,
Cyclophosphamide, and Antithymocyte Globulin Transplant
Conditioning: Results of a Dose De-Escalation TrialJohn T. Horan 1,*, Ann Haight 1, Jacqueline Lagerlof Dioguardi 2, Clark Brown 1, Audrey Grizzle 1,
Chiani Shelman 1, Julie Kanter 3, Greg Hale 4, Michael Nieder 4, Melody Benton 5,
Kimberly A. Kasow 6, Allistair Abraham2, Kuang-Yueh Chiang 1
1Aﬂac Cancer and Blood Disorders Center, Emory University/Children’s Healthcare of Atlanta, Atlanta, Georgia
2 Pediatric Hematology-Oncology, Children’s National Health System, Washington, District of Columbia
3 Pediatric Hematology-Oncology, Medical University of South Carolina, Charleston, South Carolina
4Hematology-Oncology, All Children’s Hospital, St. Petersburg, Florida
5 Pediatric Hematology-Oncology, Tulane University Health Sciences Center, New Orleans, Louisiana
6 Pediatric Hematology-Oncology, University of North Carolina, Chapel Hill, North CarolinaArticle history:
Received 22 December 2014
Accepted 14 January 2015
Key Words:
Allogeneic hematopoietic cell
transplantation
Sickle cell disease
Transplant conditioningFinancial disclosure: See Acknowl
* Correspondence and reprint re
Cancer and Blood Disorders Cen
Healthcare of Atlanta, 1405 Clifton
E-mail address: jdgsfhoran@gm
http://dx.doi.org/10.1016/j.bbmt.20
1083-8791/ 2015 American Sociea b s t r a c t
High-dose busulfan, cyclophosphamide, and antithymocyte globulin (BU-CY-ATG) is the most commonly used
conditioning regimen in HLA-matched related hematopoietic cell transplantation for children with sickle cell
disease. Disease-free survival with this regimen is now approximately 95%; however, it produces signiﬁcant
morbidity. We hypothesized we could create a less toxic regimen by adding ﬂudarabine (FLU) to BU-CY-ATG
and reduce the dosages of busulfan and cyclophosphamide. We conducted a multicenter dose de-escalation
trial with the objective of decreasing the doses of busulfan and cyclophosphamide by 50% and 55%,
respectively. Using day þ28 donor-predominant chimerism as a surrogate endpoint for sustained engraft-
ment, we completed the ﬁrst 2 of 4 planned levels, enrolling 6 patients at each and reducing the total dose of
cyclophosphamide from 200 mg/kg to 90 mg/kg. On the third level, which involved a reduction of i.v.
busulfan from 12.8 mg/kg to 9.6 mg/kg, the ﬁrst 2 patients had host-predominant T cell chimerism, which
triggered trial-stopping rules. All 14 patients survive disease-free. No patients suffered severe regimen-
related toxicity. Our results suggest BU-FLU-CY-ATG using lower dose CY could be a less toxic yet effective
regimen. Further evaluation of this regimen in a full-scale clinical trial is warranted.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Successful trials in North America and Europe estab-
lished myeloablative busulfan, cyclophosphamide, and
antithymocyte globulin (BU-CY-ATG) as the preferred con-
ditioning regimen in HLA-matched related hematopoietic
cell transplantation (HCT) for children with sickle cell dis-
ease (SCD) [1-3]. Graft rejection, which occurred in about
10% of transplants performed in the 1990s, has become
rare, possibly as a result of the widespread adoption of
leukocyte-reduced erythrocyte transfusions in the routineedgments on page 905.
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ty for Blood and Marrow Transplantation.management of the complications of SCD. With the marked
decrease in rejection, approximately 95% of children trans-
planted withmatched related donors and BU-CY-ATGwill be
disease-free survivors [1,4].
Although highly effective, BU-CY-ATG causes signiﬁcant
short- and long-term morbidity. Acutely, high-dose BU-CY
produces prolonged and severe pancytopenia, resulting in
the potential for invasive infections and the need for
aggressive erythrocyte and platelet transfusion support
[5,6]. BU-CY also causes serious nonhematologic acute
toxicities, including mucositis and hepatic sinusoidal
obstruction syndrome [5,6]. Although transplant-related
mortality is rare in children with SCD, these acute
regimen-related complications diminish their health-
related quality of life and increase their initial length of
stay [7]. Transplant-related hypogonadism is the most
Table 1
Criteria for Severe SCD
Prior clinical stroke
Asymptomatic but severe cerebrovascular disease as evidenced by 1 of
the following:
 Progressive silent cerebral infarction, as demonstrated by serial
magnetic resonance imaging scans showing a succession of lesions
(2 temporally discreet lesions, each measuring 3 mm in greatest
dimension on most recent scan) or the enlargement of a single lesion,
initially measuring 3 mm
 Cerebral arteriopathy, as evidenced by abnormal TCD testing
(conﬁrmed elevated velocities in any single vessel of TAMMV  200
cm/s for nonimaging TCD or TAMX > 185 cm/s for imaging TCD)
 Signiﬁcant vasculopathy on MRA (>50% stenosis of 2 arterial seg-
ments or complete occlusion of any single arterial segment)
Frequent (3 per year for preceding 2 yr) painful vaso-occlusive
episodes (deﬁned as episode lasting 4 h and requiring
hospitalization or outpatient treatment with parenteral opioids)*
Recurrent (3 in lifetime) acute chest syndrome events that have
necessitated erythrocyte transfusion therapy
Any combination of 3 acute chest syndrome episodes and vaso-
occlusive pain episodes (deﬁned as above) yearly for 3 yr*
TCD indicates transcranial Doppler ultrasonography; TAMMV, time-
averaged mean of the maximum velocity; TAMX, time-averaged mean
maximum; MRA, magnetic resonance angiography.
* If patients were on hydroxyurea and its use had been associated with a
decrease in the frequency of episodes of acute chest syndrome or painful
vaso-occlusion (criteria 3 and 5), the frequency could be gauged from the 3
years before the start of this drug.
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infertility often deters many suffering from SCD from
pursuing HCT [10,11]. Less toxic conditioning regimens are
therefore needed.
We reasoned that we could create a less toxic regimen by
adding ﬂudarabine to BU-CY-ATG, using it to reduce the
dosages of both busulfan and cyclophosphamide and still
achieve engraftment. Fludarabine is a highly immunosup-
pressive and relatively nontoxic purine analogue [12] that
has successfully been incorporated into many reduced-
toxicity, reduced-intensity, and minimally toxic condition-
ing regimens [13-18]. To test our hypothesis, we conducted a
multicenter dose de-escalation trial. Our objective was to
reduce the doses of busulfan and cyclophosphamide by 50%
and 55%, respectively.METHODS
Study Design and Patients
This study was opened in 2009 as a single-arm, dose de-escalation trial
by the Aﬂac Cancer and Blood Disorders Center of the Children’s Healthcare
of Atlanta and Emory University. In 2011, it was converted into a multicenter
trial and opened at 10 sites. The trial was coordinated by the Aﬂac Center’s
clinical research ofﬁce. The trial was open to childrenwith hemoglobin SS or
hemoglobin Sb0 thalassemia aged 18 years or less with an unaffected HLA-
identical sibling donor. Centers were encouraged to use bone marrow
grafts; however, cord blood units providing a total nucleated cell (TNC)
count >5.0  107/kg recipient weight could be used in place of marrow.Table 2
Dose De-Escalation Schema
Agent
Fludarabine
(Total Dosage)
Busulfan
(Total Dosage)
% Dec
Standard BU-CY-ATG d 12.8 mg/kg d
Level 1 105 mg/m2 12.8 mg/kg 0
Level 2 105 mg/m2 12.8 mg/kg 0
Level 3 150 mg/m2 9.6 mg/kg 25
Level 4 150 mg/m2 6.4 mg/kg 50Patients had to have clinically severe SCD, meeting at least 1 of the criteria
shown in Table 1.
Protection of Human Subjects
The protocol was approved by the Emory University and all local insti-
tutional review boards. Informed consent was obtained from parent/legal
guardian or patient, as appropriate, for all patients and assent obtained in
accordance with local institutional review board requirements. A rule
closing the study to enrollment for 2 deaths was used. This trial was
monitored for safety by the Aﬂac Cancer and Blood Disorders Center Data
and Safety Monitoring Board.
Treatment Protocol
Using a regimen comprising 16 i.v. doses of .8 mg/kg busulfan (12.8 mg/
kg total), 4 doses of 50 mg/kg cyclophosphamide (200 mg/kg total), and 3
doses of 30mg/kg horse ATG (90mg/kg total) as the standard [4], our 4-dose
levels comprised 2 reductions in cyclophosphamide followed by 2 re-
ductions in busulfan (Table 2). The standard ATG dose was maintained.
Fludarabine was incorporated at a total dose of 105 mg/m2 for the ﬁrst 2
dose levels and was then increased to 150 mg/m2 for the second 2 dose
levels. Busulfan was to be administered at .8 mg/kg/dose i.v. every 6 hours
for 16 doses (dose level 1 and 2: days 8 to 5), 12 doses (dose level 3:
days 7 to 5), or 8 doses (dose level 4: days 6 and 5). Busulfan phar-
macokinetic testing was performed with the ﬁrst dose and dosing adjusted
as necessary to achieve a predicted average (over all doses) area under the
curve (AUC) of 900 to 1100 mmole $min/L or a concentration steady state of
600 to 750 ng/mL. Cyclophosphamide was to be administered at 45 mg/kg
i.v. daily for 3 days (ie, days 4 to2; dose level 1) or at 30 mg/kg for 3 days
(dose levels 2, 3, and 4). Fludarabine was to be administered at 35mg/m2 i.v.
daily on days 4 to 2 (dose levels 1 and 2) and at 30 mg/m2 on days 6
to 2 (dose levels 3 and 4). For children weighing more than 125% of their
ideal body weight, chemotherapy dosing was based on adjusted ideal body
weight. ATG (Atgam, Pﬁzer, New York, NY) was administered 30 mg/kg i.v.
daily on days 4, 3, and 2. Dosing was based on actual body weight.
Two endpoints were considered in the de-escalation schema: day þ28
donor-predominant engraftment and severe regimen-related toxicity.
Day þ28 donor-predominant engraftment was deﬁned as myeloid recovery
(absolute neutrophil count 500/mL by day þ28) with most engrafting cells
being donor derived (dayþ28 chimerism showing>50% of peripheral blood
CD3þ and CD33þ cells to be donor derived). This endpoint was derived from
experience showing that early donor-predominant engraftment, especially
T cell engraftment, is a strong predictor of sustained engraftment in adults
with hematologic malignancies who receiveminimally toxic conditioning as
well as children with malignant or nonmalignant diseases who receive
myeloablative or reduced-intensity conditioning [19-21]. Severe regimen-
related toxicity was deﬁned as grade 3 or 4 regimen-related organ toxicity
occurring by day 42 using the Bearman criteria [22]; in this criteria toxicity
is graded from 1 to 4, with grade 4 toxicity being fatal.
Up to 6 patients were enrolled at each dose level. If there were 2 or more
cases where donor-predominant engraftment failed to occur, the current
dose level and all subsequent dose levels were to be closed to further
enrollment. Regimen-related toxicity was only considered in the de-
escalation criterion for dose level 1. If there were 3 or more major
toxicities at this dose level, then it would be closed to further enrollment,
and dose level 2 would be tested. Enrollment was interrupted between
patients as needed to assess these endpoints.
For post-transplant immune suppression, cyclosporine and metho-
trexate were administered to marrow recipients and cyclosporine and
mycophenolate mofetil to cord blood recipients. Cyclosporine administra-
tion commenced on day 2 using the i.v. formulation and subsequently
converted to oral as patients were able to tolerate; doses were adjusted to
maintain a level of 200 to 300 ng/mL by the TDxmethod (or equivalent level
for other cyclosporine testing methods). In the absence of graft-versus-hostrease Cyclophosphamide
(Total Dosage)
% Decrease Horse ATG
(Total Dosage)
200 mg/kg d 90 mg/kg
135 mg/kg 32.5 90 mg/kg
90 mg/kg 55 90 mg/kg
90 mg/kg 55 90 mg/kg
90 mg/kg 55 90 mg/kg
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completed by day 180. Methotrexate was administered at a dose of 15 mg/
m2 i.v. (based on actual weight) on day þ1 and at 10 mg/m2 i.v. on days þ3
and 6 and 11. Mycophenolate mofetil was administered as 15 mg/kg/dose
(maximum dose, 1000 mg) orally (or i.v. if necessary) three times day from
day 2 through day þ30. Acute and chronic GVHD were characterized ac-
cording to the U.S. National Institutes of Health consensus criteria [23,24].
All patients were given levetiracetam to prevent busulfan- and
cyclosporine-induced seizures and amlodipine to prevent cyclosporine-
induced hypertension. Supplemental magnesium beginning on day 2
was recommended to prevent cyclosporine-induced hypomagnesemia.
Granulocyte colony-stimulating factor was administered when the absolute
neutrophil count failed to reach 500/mL by day þ21 or earlier in the man-
agement of infection.
Erythrocyte transfusions, simple or exchange, were administered pre-
transplant as needed to reduce the hemoglobin S percentage to less than
30% pretransplant. Thereafter, erythrocyte transfusions were administered
to maintain the hemoglobin level between 9.0 and 11.0 g/dL. Platelets were
transfused for platelet counts <50,000/mL. Prevention and treatment of
infection was administered according to local practices.Correlative Studies
A secondary aim of this study was to characterize the cerebrovascular
effects of HCT using 2 magnetic resonance imaging biomarkers of ischemic
injury, cortical thickness measurement, and diffusion tensor imaging with
tract-based spatial statistics and plasmamarkers of endothelial injury. These
assessments are ongoing, and the results will be reported at a later date.RESULTS
Baseline Characteristics
Fourteen subjects were enrolled between 2009 and 2013.
The ﬁrst 4 subjects were enrolled in Atlanta. With the
opening of the trial to other centers in 2011, 6 of the last 10
subjects were enrolled by 4 other centers. The study was
closed to enrollment in February 2014 after the primary
endpoint was met.
Subjects ranged in age from 4 to 16 years (Table 3). All had
hemoglobin SS disease. As in the original North American
multicenter trial, cerebrovascular disease was the leading
indication for transplant [3]. Unlike that study, however,
where overt stroke accounted for almost all such cases, in our
study, 4 of 8 participants with cerebrovascular disease
qualiﬁed for the study by virtue of having abnormal trans-
cranial Doppler velocities. Thirteen participants received
bone marrow as their primary graft. Two of these partici-
pants also received small cord blood units in addition to the
marrow grafts. The median TNC and CD34þ cell marrowTable 3
Baseline Patient, Disease, and Transplant Characteristics
Patient Stratum Recipient
Age (yr)/Sex
Type
of SCD
Indication
for HCT
Donor
Age (yr)/Sex
1 1 9/M Hgb SS Clinical stroke 3/M
2 1 10/F Hgb SS Clinical stroke 18/F
3 1 15/M Hgb SS Frequent VOC/
recurrent ACS
10/F
4 1 5/F Hgb SS Recurrent ACS 4/F
5 1 4/F Hgb SS Abnormal TCD 1/F
6 1 10/M Hgb SS Clinical stroke 1/F
7 2 11/M Hgb SS Recurrent ACS 8/F
8 2 13/M Hgb SS Recurrent ACS 19/M
9 2 4/M Hgb SS Abnormal TCD 10/M
10 2 8/F Hgb SS Abnormal TCD 25/F
11 2 5/F Hgb SS Abnormal TCD 7/F
12 2 10/M Hgb SS Recurrent ACS 13/F
13 3 16/F Hgb SS Frequent VOC 19/F
14 3 5/M Hgb SS Clinical stroke 11/M
CMV indicates cytomegalovirus; R/D, recipient/donor; Hgb, hemoglobin; BM, bon
blood.
* Patient also received cord blood unit from the same donor (.8  106 TNC/kg).
y Patient also received cord blood unit from same donor (1.7  106 TNC/kg).doses were 2.8  108/kg recipient (range, .8 to 5.3) and 6.7 
106/kg recipient (range, 1.0 to 14.2), respectively. Patient 7
(dose level 2) received a cord blood unit, providing 5.1 107
TNC/kg and 3.9  105 CD34þ cells/kg as the primary graft.
The targeted expected average busulfan AUC of 900 to 1100
mmole $ min/L was achieved in all but 1 participant (864
mmole $min/L). The median expected AUC was 968mmole $
min/L (range, 864 to 1093).
Initial Donor Engraftment and Regimen-Related Toxicity
The ﬁrst 2 patients on dose level 3 failed to meet the
threshold of donor-predominate engraftment (>50% donor-
derived cells) on day þ28, which triggered the stopping
criteria for enrollment. Patients 13 and 14 had dayþ28 donor
T cell chimerisms of 38% and 26%, respectively (Table 4). Of
note, Patient 13 experienced neutrophil recovery on dayþ13
and donor myeloid chimerism was 100%. Patient 14 experi-
enced neutrophil recovery on day þ22. Myeloid chimerism
was unable to be assessed, but whole blood chimerism was
64%. For the 12 participants enrolled before dose level 3, we
failed to achieve day þ28 donor-predominant engraftment
in 2 (1 from level 1 and 1 from level 2). Patient 5’s (dose level
1) initial T cell chimerism was 45% donor. Donor myeloid
chimerism was 98%, and neutrophil recovery occurred on
day þ21. Patient 7 (dose level 2), whose primary graft was a
cord blood unit, had 26% donor T cell chimerism. Donor
myeloid chimerism was 92%, and neutrophil recovery
occurred on day þ32. None of the participants experienced
severe regimen-related toxicity.
Hematologic Outcomes and Long-Term Chimerism
At the time of last follow-up, 8 patients had reached
the 24-month mark, and the length of follow-up in the
other 6 patients ranged from 9 to 23 months (Table 2).
Disease-free survival was 100%. No patient required
erythrocyte transfusion support at last follow-up. The
median days of neutrophil and platelet recovery (using
50,000/mL as the threshold) were 22 (range, 13 to 32) and
32 (range, 18 to 62). The median number of erythrocyte
and platelet transfusions administered post-transplant
were 3 (range, 0 to 9) and 12.5 (range, 3 to 28) (Table 5).
The median of the most recent hemoglobin level was 12.8
g/dL (range, 9.9 to 15.4). The hemoglobin S percentageCMV Serostatus
(R/D)
Graft TNC
(per kg)
CD34þ
(per kg)
Estimated Average
AUC (per dose)
þ/þ BM 2.3  108 8.2  106 989
/ BM 3.9  108 5.0  106 946
þ/þ BM 2.3  108 3.1  106 997
/ BM 3.9  108 1.0  107 962
/ BM* 2.5  108 7.1  106 942
þ/ BMy .8  108 2.1  106 946
/þ CB 5.1  107 3.9  105 999
/þ BM 4.5  108 6.7  106 1093
þ/ BM 5.1  108 14.2  106 938
/ BM 1.6  108 9.0  106 973
/ BM 2.7  108 8.6  106 1011
/þ BM 2.8  108 3.4  106 906
/þ BM 4.3  108 5.2  106 988
/ BM 5.3  108 7.7  106 864
e marrow; VOC, vaso-occlusive crisis; ACS, acute chest syndrome; CB, cord
Table 4
Engraftment, Toxicity, and GVHD
Patient Stratum Length of
Follow-Up
(mo)
Day of
Neutrophil
Engraftment
Day of
Platelet
Engraftment
Grade
3/4 RRT
Day þ28
Chimerism
Acute
GVHD
Chronic
GVHD
Neurologic
Complications
Status at Last
Follow-Up
1 1 24 þ19 þ43 No 89%/100% None None None Alive, off immune
suppression, PS ¼ 100
2 1 24 þ20 þ29 No 98%/100% None None None Alive, off immune
suppression, PS ¼ 100
3 1 24 þ22 þ38 No 77%/100% None None None Alive, off immune
suppression, PS ¼ 100
4 1 24 þ22 þ33 No 89%/100% None None None Alive, off immune
suppression, PS ¼ 100
5 1 24 þ21 þ19 No 45/98% None None None Alive, off immune
suppression, PS ¼ 100
6 1 24 þ23 þ30 No 71/97% None None None Alive, off immune
suppression, PS ¼ 100
7 2 24 þ32 þ62 No 26/92% None None None Alive, off immune
suppression, PS ¼ 100
8 2 12* þ16 þ44 No 71/100% None None None Alive, off immune
suppression, PS ¼ 100
9 2 23 þ21 þ44 No 94/100 None None None Alive, off immune
suppression, PS ¼ 100
10 2 18 þ22 þ33 No 68/100% Stage 2 skin,
Grade I
Moderate PRES Remains on treatment for
chronic GVHD, PS ¼ 80
11 2 15 þ22 þ25 No 77/100$ None None None Alive, off immune
suppression, PS ¼ 100
12 2 12 þ22 þ23 No 71/98% Stage 2 skin,
Grade I
None None Alive, off immune
suppression, PS ¼ 100
13 3 9 þ13 þ18 No 38/100 None Severe None Remains on treatment for
chronic GVHD, PS ¼ 80
14 3 8 þ22 þ23 No 28/64% None None None Alive, tapering immune
suppression, PS ¼ 100
RRT indicates regimen-related toxicity; PS, performance status; PRES, posterior reversible encephalopathy syndrome.
* Lost to follow-up.
J.T. Horan et al. / Biol Blood Marrow Transplant 21 (2015) 900e905 903ranged from 0 to 3% in recipients of transplants from he-
moglobin AA donors and from 34% to 42% in recipients of
transplants from hemoglobin AS donors. In most patients,
CD3þ donor peripheral blood chimerism levels were less
than 100% initially and rose overtime. On the other hand,
in most patients, CD33þ levels started at 100% and
remained there (Figure 1).
Graft-versus-Host Disease
Patients 10 and 12 (dose level 2) developed skin-only
grade I acute GVHD that responded to treatment. Patient
10 was placed back on immune suppression, shortly after
discontinuation, because she developed chronic GVHD. HerTable 5
Hematologic Outcomes
Patient Stratum Most Recent
Hemoglobin (g/dL)
Most Recent
Hemoglobin S (%)
1 1 15.1 39.9*
2 1 13 35.9*
3 1 15.4 34
4 1 13.8 0
5 1 12.3 0
6 1 12.8 0
7 2 14.3 40*
8 2 15.2 41.8
9 2 12.9 35*
10 2 10.0 40.3*
11 2 11.9 39*
12 2 10.8 0
13 3 12.8 42*
14 3 9.9 3
PRBC indicates packed red blood cell.
* Donor had sickle cell trait.GVHD has progressed and is now severe. Of interest, the
chronic GVHD occurred after receiving an inﬂuenza vaccine.
Patient 13 (dose level 3) developed moderate chronic GVHD
without preceding acute GVHD. Patient 14 is nearing the
end of his cyclosporine taper with no signs of GVHD. All
other patients were successfully weaned off immune
suppression.Neurologic Complications
Patient 10 developed posterior reversible encephalopathy
syndrome shortly after initiating treatment (cyclosporine
and prednisone) for her chronic GVHD. All clinical and acuteNumber of PRBC Transfusions
Post-Transplant
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Post-Transplant
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Figure 1. (A) Changes in CD3þ peripheral blood chimerism level over time. (B) Changes in CD33þ peripheral blood chimerism level over time.
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resolved.
DISCUSSION
In this multicenter trial, we demonstrated the feasibility
of reducing exposure to cyclophosphamide but not busulfan.
As a result, we did not achieve our goal of cutting the
exposure to alkylating agents in children receiving BU-CY-
ATG for SCD in half. All 6 patients enrolled on dose level 2
achieved sustained donor engraftment, suggesting it may be
possible to maintain excellent disease-free survival using 90
mg/kg of cyclophosphamide rather than 200 mg/kg. A full-
scale clinical trial is needed to conﬁrm this.
Some may question our decision to use day þ28 periph-
eral blood donor-predominant chimerism (myeloid and T
cell) rather than sustained donor engraftment to guide our
dose de-escalation. We used early host predominant
chimerism, a risk factor for rejection, rather than rejection
itself for pragmatic and ethical reasons. Most cases of
rejection occur months and somemore than half a year post-
transplant [3]. Also, graft rejection in patients receiving BU-
CY-ATG is now a rare event, affecting no more than 5% of
patients [1,4]. To have used rejection as the primary endpointwould have required a sample size and interval of observa-
tion impractical for a dose de-escalation trial in this setting.
Using a risk factor for rejection rather than rejection also
enabled us to minimize the potential harm to the children
participating in the trial.
All 3 dose combinations we tested were acutely well
tolerated. This is shown by the absence of hepatic sinusoidal
syndrome, a relatively common complication in children
with SCD receiving standard BU-CY-ATG [4]. With our focus
on short-term outcomes and limited sample size, we were
unable to assess the effects of the dose reductions on
reproductive function; however, given our failure to reduce
the dose of the highly gonadotoxic busulfan [25,26], it is
unlikely we materially lessened gonadotoxicity. Those of us
who care for these children need to make the development
of a nongonadotoxic approach a priority.
It is notable that only 1 of 14 participants suffered
neurologic toxicity. This is considerably lower than the in-
cidences in previous multicenter studies. Although with our
limited sample size we cannot exclude this was due to
chance alone, patient or treatment differences could also
account for the difference. For seizure prophylaxis we used
levetiracetam instead of phenytoin and other older
J.T. Horan et al. / Biol Blood Marrow Transplant 21 (2015) 900e905 905anticonvulsants used in previous studies [2,3]. It may be that
levetiracetam is more effective in this setting. Also, the fact
that half of the patients we transplanted for cerebrovascular
disease had not previously suffered stroke may have been
important. Although the etiology of transplant-related
neurologic toxicity remains poorly understood, it is
conceivable that patients with less parenchymal damage are
less prone to these complications.
We quantiﬁed the amount of transfusion support SCD
patients receive after transplant for the ﬁrst time. Our data
indicate that the number of transfusions required, both
erythrocyte and platelet, varies considerably from patient to
patient, and many require substantial platelet transfusion
support. Certainly, the use of a higher threshold (50,000/mL),
used to prevent intracranial hemorrhage [3,27], accounts in
large part for the considerable platelet transfusion require-
ment. However, other factors may also be important. HLA
alloimmunization could inﬂuence need for platelet trans-
fusion support, because alloimmunization to class I antigens,
which are expressed by platelets, is prevalent in children
with SCD [28,29].
In conclusion, the results of our dose de-escalation trial
demonstrate that by adding ﬂudarabine to BU-CY-ATG, it is
feasible to reduce the dose of cyclophosphamide needed to
achieve donor engraftment in children with SCD receiving
matched related donor transplants. A full-scale multi-insti-
tutional clinical trial is needed to conﬁrm that this 4-drug
regimen can maintain disease-free survival at 95%.
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